Odiparcil iMProveS MPS

Dermal fibroblasts from a MPS VI patient overloaded with GAG. Source: Company data.

On Dec 18th, 2019 Inventiva announced positive results from the phase IIa iMProveS study, evaluating odiparcil for the treatment of mucopolysaccharidosis (MPS) type VI in adult patients. The 6-months trial confirmed odiparcil’s good overall safety profile and showed improvements in patients taking odiparcil (with or without ERT) with respect to cardiac and lung function as well as corneal clouding.

We at Inventiva would like to thank all patients, caregivers, patient associations and investigators for their confidence in and commitment to this first clinical trial of odiparcil in MPS patients. With first evidence in hand that odiparcil can bring new therapeutic options to MPS VI patients we are committed to continue the development in adults and children. As a next step we will put in place (i) an open-label extension to the iMProveS study for patients who took part in the iMProveS study and (ii) a phase I/II study in children with MPS VI (5-15 years of age), Safe-KIDDS. If you are interested in learning more about the Safe-KIDDS trial, please do not hesitate to contact us at SAFE-KIDDS@inventivapharma.com.

Click here for the full press release including a statement from Professor Chris Hendriksz

First GAG clearance therapy

First GAG clearance therapy

Odiparcil (IVA336) is a small molecule developed by Inventiva Pharma with the potential to become the first oral GAG clearance therapy for Mucopolysaccharidosis I, II, IVA, VI and VII. Odiparcil has received orphan drug designation by the FDA and EMA.

Major unmet medical need

In contrast to recombinant enzymes, which constitute the current standard of care, odiparcil can be given orally and is more widely distributed in the body. For instance distribution and exposure data generated in rodents show that odiparcil reaches the heart, joints, cartilage and cornea. Many MPS patients suffer from heart problems, stiff joints, spinal cord compression and visual impairment where enzyme replacement therapy (ERT) has limited efficacy.

Demonstrated safety and tolerability

Odiparcil has demonstrated good tolerability, safety and efficacy in phase I and phase IIa clinical studies , in approximately 700 healthy volunteers and 1100 patients and it’s unique mechanism of action  has been investigated in several preclinical models.

The iMProveS trial

Inventiva has completed a 26 week, double blinded, randomized, placebo controlled phase IIa clinical study to investigate the safety, pharmacokinetics and efficacy of oral administration of odiparcil in adult patients with MPS type VI receiving enzyme replacement therapy (ERT). The study also had an open label arm with patients currently not on ERT. The headline results were released on Dec 18th, 2019.

Our Contact

For further information on the iMProveS trial please contact us

Phone +33 (0) 380 447 500 - Ask for Mireille Tallandier
Address Inventiva Pharma - 50, rue de Dijon - 21121 Daix, France
SerbiaLithuaniaSwedishItalyTurkeyPortugalSaudi ArabiaSpainGermanFrench